Ionis Pharmaceuticals, Inc. (IONS) Stock Score, Valuation & Financial Research
Ionis Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 16/100.
Quick answer for IONS
Ionis Pharmaceuticals, Inc. currently has a Wall Street Score of 16/100. The stored market price is $54.21. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -1.5 points. These figures are a research snapshot, not a buy or sell recommendation.
What Ionis Pharmaceuticals, Inc. does
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG);
IONS financial snapshot
- Wall Street Score:
- 16/100
- Current price:
- $54.21
- Market capitalization:
- $9.01B
- Revenue:
- $873.8M
- Net income:
- $-564.8M
- Free cash flow:
- $-320.0M
- Cash:
- $350.1M
- Total debt:
- $2.42B
- EPS:
- -2.38
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 9/100
What stands out
- Reported year-over-year revenue growth is -0.1%.
- Free cash flow is $-320.0M, showing cash burn in the current stored period.
- The balance sheet shows $350.1M of cash versus $2.42B of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -1.5 points: IONS decreased 1.5 points because Revenue declined by 12.3 points, Asset declined by 2.9 points, Buffett declined by 2.9 points.
- The current research record carries a high debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research IONS
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.